74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Organovo Holdings Inc
Closed
0.34
Overview
Share price change
24h
Min
0.34
Max
0.36
Income | 795K -2.5M |
|---|---|
Sales | -9K 30K |
EPS | -0.19 |
Profit margin | -8,496.667 |
Employees | 19 |
EBITDA | 776K -2.5M |
Next Earnings | 26 Feb 2025 |
|---|
Market Cap | 5.8M |
|---|---|
Previous open | 0.34 |
Previous close | 0.34 |
Technical Score
By Trading Central
Confidence
Strong Bullish Evidence
Organovo Holdings Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Organovo Holdings Inc Forecast
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Organovo Holdings Inc
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company's lead candidate is FXR314, which is phase 2/3clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus steatohepatitis. Organovo Holdings, Inc. has research collaborations with Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia for research of NovoGen Bioprinters. The company was incorporated in 2007 and is headquartered in San Diego, California.
